Sriram Ryali

Director Financiero/CFO en CODEXIS, INC. .

Fortuna: 172 939 $ al 30/04/2024

43 años

Health Technology

Consumer Services

Process Industries

Cargos activos de Sriram Ryali

Empresas	Cargo	Inicio	Fin
CODEXIS, INC.	Comptroller/Controller/Auditor	23/01/2023	-
CODEXIS, INC.	Director Financiero/CFO	23/01/2023	-

Empresas	Cargo	Inicio	Fin
EIGER BIOPHARMACEUTICALS, INC.	Director Financiero/CFO	03/12/2018	20/01/2023
	Contacto de Relaciones con Inversores	03/12/2018	20/01/2023
	Public Communications Contact	03/12/2018	20/01/2023
AIMMUNE THERAPEUTICS, INC.	Corporate Officer/Principal	01/12/2017	01/12/2018
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Director Técnico/Científico/I+D	01/01/2013	01/01/2015
	Corporate Officer/Principal	01/01/2011	01/01/2015
JAZZ PHARMACEUTICALS PLC	Corporate Officer/Principal	01/01/2015	-

University of California, Los Angeles	Undergraduate Degree
UCLA Anderson School of Management	Masters Business Admin

Internacional

Estados Unidos	7
Irlanda	2

Operativa

Corporate Officer/Principal	3
Director of Finance/CFO	2
Investor Relations Contact	1

Sectorial

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	3
EIGER BIOPHARMACEUTICALS, INC.	Health Technology
JAZZ PHARMACEUTICALS PLC	Health Technology
CODEXIS, INC.	Process Industries

Empresas privadas	2
Aimmune Therapeutics, Inc. Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.	Health Technology
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology

Empresas privadas

Health Technology